APPLICATIONS IN ALLERGY DIAGNOSIS AND THERAPY
The primary interest of our group is the development of new tools for allergy diagnosis and for safer and more efficient allergen-specific immunotherapy.
Type I allergies, which comprise a wide range of IgE-mediated disorders such as hay fever, asthma, atopic dermatitis, affect more than 20% of the population and therefore represents a major health problem.
Presently, we are working on birch pollen and associated food allergies, allergic reactions to mountain and Japanese cedar and ragweed and mugwort pollen allergies. To generate improved tools for allergy diagnosis and therapy, our ongoing projects involve:
- Identification of natural allergens
- Generation of low IgE binding hypoallergenic molecules in bacterial, yeast and plant expression systems
- Protein purification
- Physicochemical protein characterization (analysis of protein folding and aggregation, mass spectrometry)
- Immunologic characterization of recombinant proteins in vitro
- Antigen uptake and processing
- Analysis of allergenic molecules in pre-clinical models
We are happy to tell you about four recent publications!
High-affinity Bet v 1-specific secretory IgA antibodies in nasal fluids protect against birch pollen allergy
Chemical modification of ragweed extract results in an increased safety profile while maintaining immunogenicity.
Hydrogen/deuterium exchange memory NMR reveals structural epitopes involved in IgE cross-reactivity of allergenic lipid transfer proteins
Purification and biochemical characterization of Hel a 6, a cross-reactive pectate lyase allergen from Sunflower (Helianthus annuus L.) pollen
EAACI explains vaccinations
To vaccinate or not to vaccinate? This question raises a great deal of discussion. To find out what a group of international scientists and experts of the immune system have to say about it, take a look at our short and informative animated video.
The research group is part of the international FWF Doktoratskolleg “Immunity in Cancer and Allergy” (ICA) of the University of Salzburg.
The research group is member of the “ Allergy-Cancer-BioNano Research Centre” (ACBN) of the University of Salzburg.